~~<i id='ACC21BDCA7'><strike id='ACC21BDCA7'><tt id='ACC21BDCA7'><pre id='ACC21BDCA7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：entertainment 2025-09-07 13:59:21 - browse：59853

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Drug companies' payments and gifts affect physicians' prescribing

knowledge

entertainment

knowledge

focus

explore

hotspot

HumanasuedthefederalgovernmentFridayoverarulethatclawsbackoverpaymentsfromitandotherMedicareAdvantag

WSS

NIH nominee Bertagnolli will get October confirmation hearing

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Stem cell treatment guidelines are released by FDA

Drug companies' payments and gifts affect physicians' prescribing

Illumina names Agilent executive as new CEO

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

hotspot

knowledge

knowledge

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Harvard scientists, with Google, unveil the most detailed brain map ever

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Florida Supreme Court upholds state's abortion ban

Apple is now the first public company to be valued at $3 trillion

Amazon on where the company's health care bets are headed next

Peter Hotez and the public health issue of online harassment

Insurer loopholes limit power of law against surprise medical bills

Walensky prepares to leave CDC — and Congress — behind

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

entertainment

Listen: Biogen's potential pivot, & Illumina's next chapter

Why Novartis is changing the name of its research labs

Republican states more likely to report Covid vaccine side effects

A new House health package & hospitals’ new site

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Stem cell treatment guidelines are released by FDA

knowledge

focus

explore

hotspot